Calamos Advisors
TMCI icon

Calamos Advisors’s Treace Medical Concepts TMCI Stock Holding History

Calamos Advisors’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-154,074
Closed -$3.94M – 991
2023
Q2 		$3.94M Sell
154,074
-25,568
-14% -$660K 0.02% 599
2023
Q1 		$4.53M Buy
179,642
+17,087
+11% +$401K 0.02% 655
2022
Q4 		$3.74M Sell
162,555
-65,885
-29% -$1.52M 0.02% 718
2022
Q3 		$5.04M Buy
+228,440
New +$4.42M 0.02% 672

Other funds holding TMCI

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calamos Advisors's TMCI Position: Q3 2023 in Review

Calamos Advisors sold out of Treace Medical Concepts (TMCI) in Q3 2023, closing a stake of 154,074 shares — an estimated $3.94M sold.

Calamos Advisors first reported a position in TMCI in Q3 2022 and held it in 4 quarters. The position peaked at $5.04M in Q3 2022. 123 funds tracked by Wall St. Rank hold TMCI as of Q3 2023.

  • Calamos Advisors reported no remaining Treace Medical Concepts position as of Q3 2023 after selling out during the quarter.
  • Calamos Advisors sold 154,074 Treace Medical Concepts shares in Q3 2023, an estimated $3.94M.
  • Calamos Advisors first reported a position in Treace Medical Concepts in Q3 2022 and held it in 4 quarters.
  • Calamos Advisors's Treace Medical Concepts position peaked at $5.04M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2023.

Based on Calamos Advisors's 13F filing for Q3 2023, filed 26 Oct 2023.